Announcement of the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final ...

Omvoh (mirikizumab-mrkz) for moderately to severely active Crohn’s disease in adults. Omvoh is now approved in the U.S. for ...

The U.S. Food and Drug Administration has approved Eli Lilly's Omvoh (mirikizumab-mrkz) for the treatment of moderately to ...

Potential antitrust deregulation could foster a more favourable environment for larger M&A deals, though skepticism remains.

These high-quality stocks continuously grow, maintain an edge over competitors, and make more money than the business needs.

We examine trademark litigation data to reveal how rival drugmakers Novo Nordisk and Eli Lilly are aggressively enforcing ...

Novo Nordisk (NVO) stock slipped after ate-stage trial data for a higher-dose version of its popular obesity therapy, ...

Expect to see the pace accelerate at the Eli Lilly and Co. project on Lebanon’s north side as weather warms. The $9 million ...

Eli Lilly (NYSE: LLY) began a roll in late 2020 that lasted almost four years. During that time, it became the world's ...

Current laws and regulations are not enough to protect Americans from the risks of compounded versions of popular weight loss ...

More than half (53%) of patients reached remission after one year of Omvoh treatment and 46% experienced healing of the ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...